UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 __________________________ ...

Arvinas (NasdaqGS:ARVN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAndrew Saik - CFOAngela Cacace - Chief Scientific OfficerJeff Boyle - Head of Investor RelationsJonathan Miller - Managing Director of Biotech and Pharma Equity ResearchNoah Berkowitz - Chief Medical OfficerRandy Teel - President and CEOConference Call ParticipantsDaniel Bronder - AnalystSudan Loganathan - Managing Director and Equity Research AnalystTed Tenthoff - Managing Director and Senior Research AnalystTer ...

Arvinas (NasdaqGS:ARVN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAndrew Saik - CFOAngela Cacace - CSOJeff Boyle - Head of Investor RelationsJonathan Miller - Managing Director of Biotech and Pharma Equity ResearchManoj Radder - VPNoah Berkowitz - CMORandy Teel - President and CEOSrikripa Devarakonda - VP of Biotechnology Equity ResearchConference Call ParticipantsDaniel Bronder - Research AnalystDerek Archila - Managing Director and Co-Head of Therapeutics Research & Senior Bi ...

Arvinas (NasdaqGS:ARVN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker14Thank you. I will now turn the call over to Jeff Boyle, Head of Investor Relations. Jeff, you may begin.Speaker9Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release with our fourth quarter and full year 2025 financial results, which is available in the investor and media section of our website at arvinas.com. Joining us on the call today, we have Randy Teel, our President and CEO, N ...

– ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno- oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and Director – – Com ...

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson’s disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-02 ...

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webc ...

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - The appointment of Randy Teel, Ph.D., as President and CEO of Arvinas is expected to drive the company's strategy and innovation, positioning it for continued growth and momentum in the biotechnology sector [1][3]. Leadership Transition - Randy Teel succeeds John Houston, Ph.D., who is retiring but will remain on the Board and provide consulting services [2]. - Briggs Morrison, M.D., has been elected as the new Chair of the Arvinas Board of Directors [2]. Executive Background - Dr. Teel has been with Arvinas since 2018 and has over 20 years of experience in the biopharmaceutical industry, playing a key role in the company's IPO and strategic initiatives [3]. - His previous roles include Chief Business Officer and interim Chief Financial Officer, with experience at Alexion Pharmaceuticals and McKinsey & Company [3]. Strategic Focus - Dr. Teel aims to build on the existing momentum and focus on earlier stage clinical programs that have the potential to transform treatment paradigms for serious diseases [4]. - Under Dr. Houston's leadership, Arvinas achieved significant milestones, including the first positive pivotal results for a PROTAC degrader and raising over $2 billion through various funding avenues [4]. Pipeline and Future Goals - The company is advancing multiple investigational drugs, including ARV-102 for neurodegenerative disorders, ARV-393 for non-Hodgkin Lymphoma, and ARV-806 for mutated cancers [6]. - Anticipated critical milestones later this year include important clinical data from several drug candidates [5].

Core Insights - Arvinas, Inc. announced preclinical data for ARV-393 in combination with glofitamab, showing significant tumor growth inhibition in a model of diffuse large B-cell lymphoma (DLBCL) [1][3] - The company plans to initiate a Phase 1 clinical trial for this combination approach in 2026, aiming to provide a chemotherapy-free treatment option for patients with DLBCL [2][3] Group 1: Preclinical Data and Mechanism - The combination of ARV-393 (3 mg/kg) and glofitamab (0.15 mg/kg) achieved 81% tumor growth inhibition (TGI) with concomitant dosing and 91% TGI with sequential dosing, compared to 38% for ARV-393 alone and 36% for glofitamab alone [5] - At a higher dose of ARV-393 (6 mg/kg), the combination showed increased tumor regressions, with 10 out of 10 mice responding to concomitant dosing [5] - RNA sequencing indicated that ARV-393 upregulated CD20 expression and genes promoting interferon signaling, while downregulating proliferation-associated gene sets, contributing to the observed antitumor activity [5] Group 2: Clinical Development Plans - Arvinas is currently evaluating ARV-393 in a Phase 1 clinical trial for relapsed/refractory non-Hodgkin lymphoma and plans to share clinical data from this trial at a medical congress in 2026 [3] - The addition of a glofitamab combination cohort in the ongoing Phase 1 clinical trial of ARV-393 is planned for 2026 [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform, targeting various diseases including B-cell lymphomas [4][6] - The company is also advancing other investigational drugs targeting neurodegenerative disorders and mutated cancers [6]